<DOC>
	<DOCNO>NCT01233167</DOCNO>
	<brief_summary>The study aim assess effectiveness dual antiplatelet therapy , aspirin alone versus steeply discontinue clopidogrel plus aspirin prevent clinical MACE events.Our subject beyond 12-month period patient receive sirolimus drug-eluting stent implantation .</brief_summary>
	<brief_title>Effect Different Anti-platelet Strategies Long-term Outcome After Sirolimus Drug-eluting Stent Implantation</brief_title>
	<detailed_description>It clear dual antiplatelet therapy well aspirin beyond 12-months period patient receive sirolimus drug-eluting stent implantation . If aspirin plus clopidogrel reduced MACE rate without increase blood event , investigator evaluate risk-benefit ratio . The investigator observe cause mortality , nonfatal myocardial infarction , clinical-driven target vessel revascularization TVR 1-year trial duration . In addition , stroke , stent thrombosis , cardiac re-hospitalizations , dialysis/hemofiltration , duration hospitalization bleed event observe .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age 18 year old . The late PCI DES implantation 12 month ( stent must one sirolimuseluting stent ) . Angiographically confirmed major epicardial vessel ( &gt; =2.5mm diameter ) without significant stenosis restenosis ( &gt; =50 % ) . Geographically accessible willing come require study visit . Signed informed consent . The patient know hypersensitivity contraindication aspirin clopidogrel . Severe congestive heart failure ( class III IV accord NYHA , pulmonary edema ) time enrollment within 12 month . EF &lt; 35 % within 12 month . Severe cardiac valve disease , idiopathic cardiomyopathy dilate cardiomyopathy , hypotrophic cardiomyopathy . Other severe system disease . Previous ACS within 12 month . Previous stroke transient ischemia attack within 12 month . Previous myocardial infarction clinicaldriven target vessel revascularization within 12 month . Current enrollment another clinical trial . Suspected pregnancy . Big bleeding event within 12 month . Planned surgical procedure . Previous type DES implantation BMS implantation history . Extracardiac stent implantation history . Current plan dialysis . The patient know hypersensitivity contraindication statin . Current plan high dose longterm glucocorticoid treatment . expect limit survival le 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>dual antiplatelet therapy</keyword>
	<keyword>sirolimus drug-eluting stent</keyword>
	<keyword>major adverse cardiac event</keyword>
	<keyword>bleeding</keyword>
</DOC>